news
Blood tests could spot cancer and T-cells to fight it
New research shows a blood-only strategy can identify cancer neoantigens and the T-cells that recognize them. This could make personalized immunotherapy available to more patients, especially those who can't get a tumor biopsy, by spotting targets across metastatic lesions.
New research shows a blood-only strategy can identify cancer neoantigens and the T-cells that recognize them. This could make personalized immunotherapy available to more patients, especially those who can't get a tumor biopsy, by spotting targets across metastatic lesions.
The architecture take
I've always been wary of the "magic bullet" narrative in cancer, but this is a serious shift. Until now, you usually needed a tumor biopsy to figure out what unique markers (neoantigens) a cancer was waving around so your T-cells could be trained to target them. This new blood test changes that. It means identifying those targets becomes far less invasive and, crucially, can pick up signals from tumors spread throughout the body, not just the primary site. The big win here is for immunity, making advanced immunotherapy more accessible. Think how much this impacts a patient's capacity and overall load when you take away the need for repeated, invasive biopsies. It’s a huge step toward more precise, less brutal treatment protocols.